2 most recent filings and news items mentioning KAPA. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/KAPA/news?limit=20"
Pull KAPA filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKairos reported interim Phase 1 data showing zero Grade 3+ toxicity with ENV-105 in osimertinib-resistant lung cancer patients. The clean safety profile strengthens the potential for a breakthrough therapy in a substantial drug resistance market.
View filing at SEC.gov →Kairos Pharma announced a strategic acquisition of worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for NSCLC and gastric cancers, targeting a $16.2B EGFR-mutant lung cancer market. The company plans Phase 1 initiation and multiple clinical milestones through 20
View filing at SEC.gov →